VSAR Versartis, Inc. gains 15% Dec 11, 2017

Posted By: Rajesh Srivastava - Monday, December 11, 2017

Share

& Comment

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California. http://www.priceseries.com/trade/VSAR-Versartis-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2017112220171211.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.